Walsh, Jessica A.
Saffore, Christopher D.
Ye, Xiaolan
Patel, Manish
Biljan, Ana
Vora, Jamie
Truman, Isabel
Edwards, Molly
Milligan, Gary
Ostor, Andrew
Funding for this research was provided by:
AbbVie
Article History
Received: 12 August 2025
Accepted: 2 October 2025
First Online: 23 October 2025
Declarations
:
: Jessica A Walsh has received consulting fees or research grants from AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB Pharma. Chistopher D Saffore, Xiaolan Ye, Manish Patel, Ana Biljan, and Jamie Vora are employees of AbbVie Inc. and may hold stock. Isabel Truman, Molly Edwards, and Gary Milligan are employees of Adelphi Real World. Andrew Ostor has received speaker or consulting fees and/or research grants from AbbVie, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB.
: Using a checkbox, patients provided informed consent to take part in the survey. No identifiable protected health information was extracted during the survey. Data were collected in such a way that patients and physicians could not be identified directly, with data aggregated before being shared with the subscriber and/or for publication. Data collection was undertaken in line with European Pharmaceutical Marketing Research Association guidelines and as such did not require ethics committee approval. The survey materials were submitted to PEARL IRB (AG9361) and were deemed to be exempt (IRB ID 2023–0199). Each survey was performed in full accordance with relevant legislation at the time of data collection, including the Helsinki Declaration of 1964 (and its later amendments), the US Health Insurance Portability and Accountability Act 1996, and Health Information Technology for Economic and Clinical Health Act legislation [ ].